Skip to main content
SpringerLink
Log in

Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient

  • Brief Communication
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The efficacy of the serotonin antagonist ondansetron (GR 38032F) was evaluated in the prevention of nausea and vomiting induced by CMF chemotherapy in 29 breast cancer patients. At their first treatment course of CMF, all given IV on day 1 q 21 days, patients were given oral antiemetic treatment as follows: ondansetron 8 mg, 2 h prior to CMF, repeated after 5 and 10 h the day of chemotherapy and then 8 mg tds for a minimum of 3 days to a maximum of 5 days following chemotherapy. At first course of CMF, complete protection from emesis and nausea was observed in 86.2% and 62% of patients, respectively. At subsequent CMF courses with ondansetron, complete control of emesis was observed in 80% of patients. Side effects were mild and no dystonic reactions were observed. Ondansetron represents an effective, safe, and easily administered outpatient regimen. The addition of a corticosteroid to ondansetron could further improve control of CMF-induced emesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, Braun DW, Bordin LA, Braun TJ, Young CW: Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305: 905–909, 1981

    PubMed  Google Scholar 

  2. David M, Durand M, Chauvergne J, Mauriac L, Bui BN, Hoerni B: Cyclophosphamide, methotrexate and 5-FU (CMF) induced nausea and vomiting: a controlled study with high-dose metoclopramide. Cancer Treat Rep 68: 921–922, 1984

    PubMed  Google Scholar 

  3. Morran C, Smith DC, Anderson DA, McArdle CS: Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. Br Med J 1: 1323–1324, 1979

    Google Scholar 

  4. Wilcox PM, Fetting JH, Nettesheim KM, Abeloff MD: Anticipatory vomiting in women receiving cyclophosphamide, methotrexate and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep 66: 1601–1604, 1982

    PubMed  Google Scholar 

  5. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, DeLena M, Tancini G, Bajetta E, Musumeddi R, Veronesi U: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410, 1986

    Google Scholar 

  6. Kris MG, Gralla RJ, Tyson LB, Clark RA, Kelsen DP, Reilly LK, Groshen S, Bosl GJ, Kalman LA: Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 55: 527–534, 1985

    PubMed  Google Scholar 

  7. Sridhar KS, Donnelly E: Combination antiemetics for cisplatin chemotherapy. Cancer 61: 1508–1517, 1988

    PubMed  Google Scholar 

  8. Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S: Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethazone: a double-blind randomized trial. Cancer 60: 2816–2822, 1987

    PubMed  Google Scholar 

  9. Richardson BP, Engel G, Donatsch Pet al. Identification of serotonin M-receptor subtypes and their specific blockage by a new class of drugs. Nature 316: 126–131, 1985

    Article  PubMed  Google Scholar 

  10. Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojasteh A, Topazoglou E, Sartiano GP, White DR, Werner K, Chubb JM: GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7: 700–705, 1989

    PubMed  Google Scholar 

  11. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade-Lauraine E, Paule B, Paes D, Bons J: Comparison of the 5-hydroytryptamine 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322: 816–821, 1990

    PubMed  Google Scholar 

  12. Chiara S, Campora E, Lionetto R, Bruzzi P, Rosso R: Methylprednisolone for the control of CMF-induced emesis. Am J Clin Oncol 10: 264–267, 1987

    PubMed  Google Scholar 

  13. Hawthorn J, Cunningham D: Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. Br J Cancer 61: 56–60, 1990

    PubMed  Google Scholar 

  14. Smith DB, Newlands ES, Spruyt OW, Begent RHJ, Rustin GJS, Mellor B, Bagshawe KD: Ondansetron (GR 38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy. Br J Cancer 61: 323–324, 1990

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 10, 16132, Genova, Italy

    Elisabetta Campora, Cristina Oliva, Serafina Mammoliti, Maurizio Marangolo & Riccardo Rosso

  2. Chair of Medical Oncology, University of Verona, Italy

    Gian Luigi Cetto & Maurizio Marangolo

  3. Dept. of Medical Oncology, Ospedale di Vicenza, Italy

    Vinicio Fosser & Maurizio Marangolo

  4. Dept. of Medical Oncology, Ospedale di Ravenna, Italy

    Maurizio Marangolo & Riccardo Rosso

Authors
  1. Elisabetta Campora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina Oliva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Serafina Mammoliti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gian Luigi Cetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vinicio Fosser
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maurizio Marangolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Riccardo Rosso
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campora, E., Oliva, C., Mammoliti, S. et al. Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient. Breast Cancer Res Tr 19, 129–132 (1991). https://doi.org/10.1007/BF01980943

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01980943

Key words

Search

Navigation